Abstract CT110: Olaparib (O) in patients (pts) with solid tumors with <i>ATM</i> mutation or deletion: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study

Authors: Kathryn F. Mileham, Michael Rothe, Pam K. Mangat, Elizabeth Garrett-Mayer, Eddy S. Yang, Olatunji B. Alese, Angela Jain, Herbert L. Duvivier, Phillip Palmbos, Eugene R. Ahn, Jeanny B. Aragon-Ching, Kathleen W. Beekman, Deepti Behl, Funda Meric-Bernstam, Rodolfo Gutierrez, Amy Sanford, Ramya Thota, Michael Zakem, Song Zhao, Raegan O'Lone, Gina N. Grantham, Susan Halabi, Richard L. Schilsky

Published: 2022-06-15

DOI: 10.1158/1538-7445.am2022-ct110

Source: Full article